{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:01:05Z","timestamp":1793127665614,"version":"4.5.0"},"reference-count":241,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.clinthera.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T00:08:39Z","timestamp":1476749319000},"page":"2340-2372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":348,"title":["Review of Safety and Efficacy of Sleep Medicines in Older Adults"],"prefix":"10.1016","volume":"38","author":[{"given":"Jennifer L.","family":"Schroeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari E.","family":"Kurtzhalts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista A.","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari A.","family":"Mergenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.amjopharm.2006.06.006","article-title":"Management of chronic insomnia in elderly persons","volume":"4","author":"Bain","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinthera.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.smrv.2015.01.003","article-title":"Risk factors for sleep disturbances in older adults: evidence from prospective studies","volume":"25","author":"Smagula","year":"2016","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib4","first-page":"1431","article-title":"Chronic insomnia: a practical review","volume":"60","author":"Rajput","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.amjmed.2005.10.051","article-title":"Insomnia in the elderly: cause, approach, and treatment","volume":"119","author":"Kamel","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cger.2014.04.007","article-title":"Sleep in older adults: normative changes, sleep disorders, and treatment options","volume":"30","author":"Gooneratne","year":"2014","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib7","first-page":"351","article-title":"Effect of age on EEG arousals in normal sleep","volume":"21","author":"Boselli","year":"1998","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib8","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/sleep\/27.7.1255","article-title":"Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan","volume":"27","author":"Ohayon","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cub.2008.06.047","article-title":"Age-related reduction in the maximal capacity for sleep\u2014implications for insomnia","volume":"18","author":"Klerman","year":"2008","journal-title":"Curr Biol"},{"issue":"2551-2558","key":"10.1016\/j.clinthera.2016.09.010_bib10","first-page":"2559","article-title":"Sleep problems in the elderly","volume":"59","author":"Neubauer","year":"1999","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0749-0690(02)00064-2","article-title":"Sleep in the elderly. What is normal?","volume":"19","author":"Feinsilver","year":"2003","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.5664\/jcsm.27286","article-title":"Clinical guideline for the evaluation and management of chronic insomnia in adults","volume":"4","author":"Schutte-Rodin","year":"2008","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M14-2841","article-title":"Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis","volume":"163","author":"Trauer","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2296-13-40","article-title":"Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review","volume":"13","author":"Mitchell","year":"2012","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.clinthera.2016.09.010_bib15","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2009.682","article-title":"Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial","volume":"301","author":"Morin","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/sleep\/29.11.1415","article-title":"Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American Academy of Sleep Medicine Report","volume":"29","author":"Morgenthaler","year":"2006","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.clinthera.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0897190007304657","article-title":"Changes in pharmacokinetics and pharmacodynamics in the elderly patient","volume":"20","author":"Hutchison","year":"2007","journal-title":"J Pharmacy Practice"},{"key":"10.1016\/j.clinthera.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00023210-199911040-00003","article-title":"Hypnosedatives in the elderly","volume":"11","author":"Woodward","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1532-5415.2000.tb02596.x","article-title":"Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years","volume":"48","author":"Brassington","year":"2000","journal-title":"J Am Geriatr Soc"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.09.010_bib21","first-page":"S379","article-title":"Quality of life in people with insomnia","volume":"22","author":"Zammit","year":"1999","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib22","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/jama.1989.03430110069030","article-title":"Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?","volume":"262","author":"Ford","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0163-8343(97)00056-X","article-title":"The morbidity of insomnia uncomplicated by psychiatric disorders","volume":"19","author":"Weissman","year":"1997","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/sleep\/25.6.621","article-title":"Medical and socio-professional impact of insomnia","volume":"25","author":"Leger","year":"2002","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib25","series-title":"Segen\u05f3s Medical Dictionary","volume":"Vol 2016","year":"2011"},{"key":"10.1016\/j.clinthera.2016.09.010_bib26","series-title":"Definitions of common sleep terms","volume":"Vol 2016","year":"2016"},{"key":"10.1016\/j.clinthera.2016.09.010_bib27","first-page":"a501","article-title":"Benzodiazepines revisited","volume":"5","author":"Mehdi","year":"2012","journal-title":"Br J Medical Practitioners"},{"key":"10.1016\/j.clinthera.2016.09.010_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The diagnosis and management of benzodiazepine dependence","volume":"18","author":"Ashton","year":"2005","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0740-5472(91)90027-8","article-title":"History of benzodiazepine dependence","volume":"8","author":"Lader","year":"1991","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.clinthera.2016.09.010_bib30","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJMcp1412740","article-title":"Clinical practice. Insomnia disorder","volume":"373","author":"Winkelman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1592\/phco.27.1.89","article-title":"Therapeutic options for sleep-maintenance and sleep-onset insomnia","volume":"27","author":"Morin","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2016.09.010_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/archinte.164.14.1567","article-title":"Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?","volume":"164","author":"Wagner","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib34","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/gps.1811","article-title":"The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent?","volume":"22","author":"Bierman","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1176\/appi.ajp.158.6.892","article-title":"Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture","volume":"158","author":"Wang","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib36","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.comppsych.2003.12.007","article-title":"Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach","volume":"45","author":"Kan","year":"2004","journal-title":"Compr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib37","unstructured":"Halcion(R) (triazolam tablet) [package insert]. New York, NY. Pfizer; 2016."},{"key":"10.1016\/j.clinthera.2016.09.010_bib38","unstructured":"Prosom (estazolam) [package insert]. North Chicago, IL. Abbott Laboratories; 2010."},{"key":"10.1016\/j.clinthera.2016.09.010_bib39","unstructured":"Restoril (temazepam) [package insert]. Hazelwood, MO. Mallinckrodt Inc.; 2014."},{"key":"10.1016\/j.clinthera.2016.09.010_bib40","unstructured":"Dalmane (flurazepam hydrochloride) [package insert] Aliso Viejo, CA. Valeant Pharamceuticals; 2007."},{"key":"10.1016\/j.clinthera.2016.09.010_bib41","unstructured":"Doral (quazepam) [package insert] Hayward, CA. Questcor Pharmaceuticals, Inc.; 2013."},{"key":"10.1016\/j.clinthera.2016.09.010_bib42","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.110.002717","article-title":"Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology","volume":"63","author":"Saari","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib43","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"1191","article-title":"Sleep disorders","author":"Dopp","year":"2014"},{"key":"10.1016\/j.clinthera.2016.09.010_bib44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/j.2055-2335.2007.tb00754.x","article-title":"Managing insomnia in older people","volume":"37","author":"Woodward","year":"2007","journal-title":"J Pharmacy Practice Research"},{"key":"10.1016\/j.clinthera.2016.09.010_bib45","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.clpt.2004.07.009","article-title":"Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate","volume":"76","author":"Greenblatt","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0009-9236(99)90084-X","article-title":"The effect of age on the pharmacokinetics and pharmacodynamics of midazolam","volume":"65","author":"Albrecht","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/appi.ps.55.3.233","article-title":"Practical geriatrics: use of benzodiazepines among elderly patients","volume":"55","author":"Bogunovic","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2016.09.010_bib48","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.clinthera.2016.09.010_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1023\/A:1006943009192","article-title":"Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem","volume":"19","author":"Chouinard","year":"1999","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib50","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4140\/TCP.n.2011.332","article-title":"Insomnia: a therapeutic review for pharmacists","volume":"26","author":"Foral","year":"2011","journal-title":"Consult Pharm"},{"key":"10.1016\/j.clinthera.2016.09.010_bib51","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1097\/01.smj.0000243131.25116.bd","article-title":"Pharmacologic management of chronic insomnia","volume":"99","author":"Taylor","year":"2006","journal-title":"South Med J"},{"issue":"Suppl:4-7","key":"10.1016\/j.clinthera.2016.09.010_bib52","article-title":"Clinical distinctions between long-acting and short-acting benzodiazepines","volume":"53","author":"Mendelson","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib53","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/11533170-000000000-00000","article-title":"The relationship between benzodiazepine use and traffic accidents: a systematic literature review","volume":"24","author":"Smink","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.1997.03550010041037","article-title":"Benzodiazepine use and the risk of motor vehicle crash in the elderly","volume":"278","author":"Hemmelgarn","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib55","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/aje\/136.7.873","article-title":"Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers","volume":"136","author":"Ray","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib56","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/cpt1977213355","article-title":"Toxicity of high-dose flurazepam in the elderly","volume":"21","author":"Greenblatt","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib57","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1001\/jama.1989.03430230088031","article-title":"Benzodiazepines of long and short elimination half-life and the risk of hip fracture","volume":"262","author":"Ray","year":"1989","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib58","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10401230590905344","article-title":"Current patterns and future directions in the treatment of insomnia","volume":"17","author":"Winkelman","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib59","first-page":"321","article-title":"The use of benzodiazepines with particular reference to the elderly","volume":"35","author":"Fancourt","year":"1986","journal-title":"Br J Hosp Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib60","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","article-title":"Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits","volume":"331","author":"Glass","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2016.09.010_bib61","first-page":"225","article-title":"Meta-analysis of benzodiazepine use in the treatment of insomnia","volume":"162","author":"Holbrook","year":"2000","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2016.09.010_bib62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2007.08.009","article-title":"Pharmacotherapy for insomnia","volume":"24","author":"Tariq","year":"2008","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00192550","article-title":"Temazepam 7.5 mg: effects on sleep in elderly insomniacs","volume":"46","author":"Vgontzas","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib64","doi-asserted-by":"crossref","first-page":"e49113","DOI":"10.1371\/journal.pone.0049113","article-title":"Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2016.09.010_bib65","doi-asserted-by":"crossref","first-page":"e000850","DOI":"10.1136\/bmjopen-2012-000850","article-title":"Hypnotics\u05f3 association with mortality or cancer: a matched cohort study","volume":"2","author":"Kripke","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2016.09.010_bib66","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","article-title":"American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults","volume":"63","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2016.09.010_bib67","series-title":"Clinical guideline for the treatment of primary insomnia in middle-aged and older adults","year":"2016"},{"key":"10.1016\/j.clinthera.2016.09.010_bib68","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2146\/ajhp060640","article-title":"Diagnosis and treatment of insomnia","volume":"65","author":"Passarella","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2016.09.010_bib69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/ajp.146.4.529","article-title":"Benzodiazepine dependence and withdrawal in elderly patients","volume":"146","author":"Schweizer","year":"1989","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib70","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.amjmed.2010.04.006","article-title":"Management of insomnia in the geriatric patient","volume":"123","author":"Roszkowska","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib71","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/13803395.2014.928268","article-title":"The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis","volume":"36","author":"Stranks","year":"2014","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib72","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1360-0443.2003.00491.x","article-title":"Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data","volume":"98","author":"Hajak","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.clinthera.2016.09.010_bib73","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.pharmthera.2005.04.014","article-title":"Treating insomnia: current and investigational pharmacological approaches","volume":"112","author":"Ebert","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2004.06.007","article-title":"Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study","volume":"51","author":"Bertschy","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib75","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2105\/AJPH.2010.300014","article-title":"The medicalization of sleeplessness: a public health concern","volume":"101","author":"Moloney","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1016\/j.clinthera.2016.09.010_bib76","doi-asserted-by":"crossref","first-page":"e8343","DOI":"10.1136\/bmj.e8343","article-title":"Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration","volume":"345","author":"Huedo-Medina","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2016.09.010_bib77","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.5665\/sleep.3914","article-title":"Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care survey 1999-2010","volume":"37","author":"Ford","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib78","doi-asserted-by":"crossref","first-page":"673","DOI":"10.5665\/sleep.3566","article-title":"Retrospective population cohort study on hip fracture risk associated with zolpidem medication","volume":"37","author":"Lin","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3961\/jpmph.2012.45.4.219","article-title":"Zolpidem use and risk of fracture in elderly insomnia patients","volume":"45","author":"Kang","year":"2012","journal-title":"J Prev Med Public Health"},{"key":"10.1016\/j.clinthera.2016.09.010_bib80","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.mayocp.2014.01.021","article-title":"Long-term use of zolpidem increases the risk of major injury: a population-based cohort study","volume":"89","author":"Lai","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2016.09.010_bib81","series-title":"FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR","volume":"Vol 2016","year":"2016"},{"key":"10.1016\/j.clinthera.2016.09.010_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00003088-200443040-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone","volume":"43","author":"Drover","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.09.010_bib83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200721050-00003","article-title":"Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?","volume":"21","author":"Dolder","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib84","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsmc.2014.11.002","article-title":"Non-benzodiazepine receptor agonists for insomnia","volume":"10","author":"Becker","year":"2015","journal-title":"Sleep Med Clin"},{"key":"10.1016\/j.clinthera.2016.09.010_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.300.1.2","article-title":"A new benzodiazepine pharmacology","volume":"300","author":"Mohler","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.09.010_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00023210-200418001-00004","article-title":"The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents","volume":"18","author":"Sanger","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib87","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","article-title":"Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia","volume":"59","author":"Holm","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib89","series-title":"Emergency Department Visits Attributed to Overmedication that Involved the Insomnia Medication Zolpidem","year":"2014"},{"key":"10.1016\/j.clinthera.2016.09.010_bib90","unstructured":"Ambien (zolpidem tartrate) [package insert]. Bridgewater, NJ. sanofi-aventis US LLC; 2008."},{"key":"10.1016\/j.clinthera.2016.09.010_bib91","unstructured":"Lexicomp Online, Lexi-Drugs, Hudson, OH. Lexi-Comp, Inc.; 2016."},{"key":"10.1016\/j.clinthera.2016.09.010_bib92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00023210-200519010-00008","article-title":"Zolpidem: a review of its use in the management of insomnia","volume":"19","author":"Swainston Harrison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib93","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications","volume":"29","author":"Salva","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.09.010_bib94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003495-199040020-00008","article-title":"Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential","volume":"40","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib95","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/sleep\/30.5.593","article-title":"The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia","volume":"30","author":"Walsh","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib96","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1098-2299(199703)40:3<230::AID-DDR3>3.0.CO;2-L","article-title":"Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia","volume":"40","author":"Leppik","year":"1997","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib97","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5664\/jcsm.27390","article-title":"Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia","volume":"5","author":"Zammit","year":"2009","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib98","series-title":"FDA Requests Label Change for All Sleep Disorder Drug Products","author":"Walsh","year":"2007"},{"key":"10.1016\/j.clinthera.2016.09.010_bib99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/17512433.2014.864949","article-title":"Non-benzodiazepine hypnotics and older adults: what are we learning about zolpidem?","volume":"7","author":"Levy","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/hup.980","article-title":"Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers","volume":"23","author":"Otmani","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib101","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.sleep.2007.11.011","article-title":"Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam","volume":"9","author":"Gustavsen","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib102","series-title":"[package insert]","article-title":"(zolpidem tartrate extended-release)","author":"Ambien","year":"2014"},{"key":"10.1016\/j.clinthera.2016.09.010_bib103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/JGP.0b013e3181256b01","article-title":"Efficacy and safety of zolpidem extended release in elderly primary insomnia patients","volume":"16","author":"Walsh","year":"2008","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib104","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/00003495-200060020-00014","article-title":"Zaleplon: a review of its use in the treatment of insomnia","volume":"60","author":"Dooley","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib105","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0149-2918(00)83024-6","article-title":"Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia","volume":"22","author":"Weitzel","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4088\/PCC.v01n0404","article-title":"Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects","volume":"1","author":"Ancoli-Israel","year":"1999","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib107","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/1099-1166(200008)15:8<704::AID-GPS183>3.0.CO;2-S","article-title":"Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group","volume":"15","author":"Hedner","year":"2000","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.sleep.2004.10.015","article-title":"Long-term use of sedative hypnotics in older patients with insomnia","volume":"6","author":"Ancoli-Israel","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib109","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1345\/aph.1A086","article-title":"Safety of zaleplon in the treatment of insomnia","volume":"36","author":"Israel","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2016.09.010_bib110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40266-014-0211-3","article-title":"Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects","volume":"31","author":"Greenblatt","year":"2014","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2016.09.010_bib111","first-page":"441","article-title":"Eszopiclone: its use in the treatment of insomnia","volume":"3","author":"Monti","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2016.09.010_bib112","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinthera.2006.04.014","article-title":"Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia","volume":"28","author":"Najib","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib113","first-page":"313","article-title":"Eszopiclone for late-life insomnia","volume":"2","author":"McCrae","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.clinthera.2016.09.010_bib114","unstructured":"Lunesta (eszopiclone) [package insert]. Marlborough, MA. Sunovion Pharmaceuticals Inc.; 2014."},{"key":"10.1016\/j.clinthera.2016.09.010_bib115","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/17425255.2012.741588","article-title":"Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications","volume":"8","author":"Greenblatt","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib116","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/NSS.S5133","article-title":"Management of insomnia in elderly patients using eszopiclone","volume":"2","author":"Kirkwood","year":"2010","journal-title":"Nat Sci Sleep."},{"key":"10.1016\/j.clinthera.2016.09.010_bib117","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/sleep\/33.2.225","article-title":"A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep\/wake function in older adults with primary and comorbid insomnia","volume":"33","author":"Ancoli-Israel","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib118","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/sleep\/28.6.720","article-title":"A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia","volume":"28","author":"Scharf","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib119","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1185\/030079906X112741","article-title":"A polysomnography study of eszopiclone in elderly patients with insomnia","volume":"22","author":"McCall","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2016.09.010_bib120","unstructured":"Rozerem (ramelteon) tablets [package insert]. Deerfield, IL. Takeda Pharmaceuticals America, Inc.; 2010."},{"key":"10.1016\/j.clinthera.2016.09.010_bib121","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/jm0201159","article-title":"Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists","volume":"45","author":"Uchikawa","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2016.09.010_bib122","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2004.09.007","article-title":"Neurochemical properties of ramelteon (TAK-375), a selective MT1\/MT2 receptor agonist","volume":"48","author":"Kato","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2016.09.010_bib123","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0306-4522(02)00034-9","article-title":"GABA mechanisms and sleep","volume":"111","author":"Gottesmann","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.clinthera.2016.09.010_bib124","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archpsyc.63.10.1149","article-title":"Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects","volume":"63","author":"Johnson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.clpt.2003.11.085","article-title":"Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects","volume":"75","author":"Stevenson","year":"2004","journal-title":"Clinical Pharmacology Therapeutics."},{"key":"10.1016\/j.clinthera.2016.09.010_bib126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000123997","article-title":"Bioavailability of oral melatonin in humans","volume":"39","author":"Waldhauser","year":"1984","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinthera.2016.09.010_bib127","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0091270005283461","article-title":"Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia","volume":"46","author":"Karim","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000362459","article-title":"Pharmacological characterization of M-II, the major human metabolite of ramelteon","volume":"93","author":"Nishiyama","year":"2014","journal-title":"Pharmacology"},{"key":"10.1016\/j.clinthera.2016.09.010_bib129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/0091270006298602","article-title":"Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2","volume":"47","author":"Greenblatt","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/00006205-200604000-00011","article-title":"Ramelteon (rozerem) a novel approach for insomnia treatment","volume":"31","author":"Laustsen","year":"2006","journal-title":"Nurse Pract"},{"key":"10.1016\/j.clinthera.2016.09.010_bib131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.sleep.2010.08.010","article-title":"Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia","volume":"12","author":"Uchiyama","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib132","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1586\/ern.10.197","article-title":"Efficacy and safety of ramelteon in Japanese adults with chronic insomnia: a randomized, double-blind, placebo-controlled study","volume":"11","author":"Uchimura","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2016.09.010_bib133","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5664\/jcsm.26914","article-title":"Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia","volume":"3","author":"Zammit","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib134","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.smrv.2007.12.005","article-title":"Efficacy and clinical safety of ramelteon: an evidence-based review","volume":"12","author":"Sateia","year":"2008","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.sleep.2006.01.003","article-title":"Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia","volume":"7","author":"Roth","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib136","first-page":"A228","article-title":"Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia","volume":"28","author":"Zammit","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib137","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sleep.2005.09.004","article-title":"An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia","volume":"7","author":"Erman","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib138","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.amjopharm.2007.09.004","article-title":"Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty","volume":"5","author":"Mini","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinthera.2016.09.010_bib139","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/sleep\/32.3.351","article-title":"Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia","volume":"32","author":"Mayer","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib140","doi-asserted-by":"crossref","first-page":"e0136910","DOI":"10.1371\/journal.pone.0136910","article-title":"Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"10","author":"Kishi","year":"2015","journal-title":"PloS One"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.09.010_bib141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.13011su1c","article-title":"Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system","volume":"74","author":"Krystal","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib142","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s40265-014-0294-5","article-title":"Suvorexant: first global approval","volume":"74","author":"Yang","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib143","unstructured":"Belsomra (suvorexant) [package insert]. Whitehouse Station, NJ. Merck & Co. Inc.; 2014."},{"key":"10.1016\/j.clinthera.2016.09.010_bib144","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/1060028015570467","article-title":"Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia","volume":"49","author":"Patel","year":"2015","journal-title":"Ann Pharmacotherapy."},{"key":"10.1016\/j.clinthera.2016.09.010_bib145","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib146","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2016.09.010_bib147","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib148","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib149","unstructured":"Administration UFaD. FDA Drug Safety Communication: FDA approves new type of sleep drug, Belsomra. Silver Spring, MD: U.S. Food and Drug Administration; 2014. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm409950.htm"},{"key":"10.1016\/j.clinthera.2016.09.010_bib150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.sleep.2011.09.006","article-title":"Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia","volume":"13","author":"Lankford","year":"2012","journal-title":"Sleep Med"},{"issue":"Suppl E1","key":"10.1016\/j.clinthera.2016.09.010_bib151","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.9058se1c.04gry","article-title":"Major depressive disorder treatment guidelines in America and Europe","volume":"71","author":"Davidson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib152","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2125.1983.tb04977.x","article-title":"Trazodone enhances sleep in subjective quality but not in objective duration","volume":"16","author":"Montgomery","year":"1983","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl:","key":"10.1016\/j.clinthera.2016.09.010_bib153","first-page":"13","article-title":"Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients","volume":"51","author":"Scharf","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"Suppl:","key":"10.1016\/j.clinthera.2016.09.010_bib154","first-page":"S37","article-title":"Effects of trazodone on the sleep of depressed subjects\u2014a polygraphic study","volume":"95","author":"Mouret","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl:","key":"10.1016\/j.clinthera.2016.09.010_bib155","first-page":"18","article-title":"Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults","volume":"51","author":"Ware","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib156","unstructured":"Trazodone [Oleptro, package insert]. Toronto, Ontario, Canada. APOTEX Inc.; 2014."},{"key":"10.1016\/j.clinthera.2016.09.010_bib157","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2125.1983.tb02180.x","article-title":"Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly","volume":"16","author":"Bayer","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.sleep.2003.06.006","article-title":"The effects of trazodone on sleep in patients treated with stimulant antidepressants","volume":"5","author":"Kaynak","year":"2004","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib159","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1440-1819.2003.01161.x","article-title":"Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients","volume":"57","author":"Karam-Hage","year":"2003","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2016.09.010_bib160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v66n0409","article-title":"A review of the evidence for the efficacy and safety of trazodone in insomnia","volume":"66","author":"Mendelson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib161","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1440-1819.1999.00532.x","article-title":"Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: dose-finding study with no concomitant use of hypnotic agent","volume":"53","author":"Mashiko","year":"1999","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2016.09.010_bib162","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2869.2011.00928.x","article-title":"Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs","volume":"20","author":"Roth","year":"2011","journal-title":"J Sleep Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib163","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jagp.2013.12.174","article-title":"Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study","volume":"22","author":"Camargos","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib164","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0278-5846(01)00262-7","article-title":"Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone","volume":"26","author":"Saletu-Zyhlarz","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s002130050997","article-title":"Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans","volume":"144","author":"Rush","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2016.09.010_bib166","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","article-title":"Mirtazapine: a review of its use in major depression and other psychiatric disorders","volume":"23","author":"Croom","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib167","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF00278580","article-title":"Effect of the antidepressant Org 3770 on human sleep","volume":"38","author":"Ruigt","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib168","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.v64n1013","article-title":"Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia","volume":"64","author":"Winokur","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib169","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1345\/aph.10371","article-title":"Mirtazapine for treatment of depression and comorbidities in Alzheimer disease","volume":"35","author":"Raji","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2016.09.010_bib170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00443424","article-title":"An alpha 2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man","volume":"97","author":"Palazidou","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.clinthera.2016.09.010_bib171","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/(SICI)1099-1077(199611)11:6<497::AID-HUP820>3.0.CO;2-J","article-title":"Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen","volume":"11","author":"Timmer","year":"1996","journal-title":"Hum Psychopharmacol: Clin and Exp Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib172","unstructured":"Remeron (mirtazapine) [package insert]. Whitehouse Station, NJ. Merck & Co., Inc.; 2012."},{"key":"10.1016\/j.clinthera.2016.09.010_bib173","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00019442-200209000-00007","article-title":"Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients","volume":"10","author":"Schatzberg","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib174","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1002\/hup.470100807","article-title":"Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients","volume":"10","author":"Halikas","year":"1995","journal-title":"Hum Psychopharmacol: Clin and Exp Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0006-3223(00)00882-9","article-title":"Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study","volume":"48","author":"Winokur","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2016.09.010_bib176","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199512004-00006","article-title":"Safety of mirtazapine: a review","volume":"10","author":"Montgomery","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib177","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0447.1996.tb10629.x","article-title":"A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients","volume":"93","author":"Hoyberg","year":"1996","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"10.1016\/j.clinthera.2016.09.010_bib178","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/00003495-199957040-00010","article-title":"Mirtazapine: a review of its use in major depression","volume":"57","author":"Holm","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.09.010_bib179","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1001\/jama.1983.03330450047024","article-title":"Association between nutritional status and cognitive functioning in a healthy elderly population","volume":"249","author":"Goodwin","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1532-5415.1994.tb07483.x","article-title":"Nutrition and function: is there a relationship between body mass index and the functional capabilities of community-dwelling elderly?","volume":"42","author":"Galanos","year":"1994","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2016.09.010_bib181","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1532-5415.1998.tb04537.x","article-title":"The association of weight change in Alzheimer\u05f3s disease with severity of disease and mortality: a longitudinal analysis","volume":"46","author":"White","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2016.09.010_bib182","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1532-5415.1995.tb05803.x","article-title":"Involuntary weight loss in older outpatients: incidence and clinical significance","volume":"43","author":"Wallace","year":"1995","journal-title":"J Am Geriatr Soc"},{"issue":"52","key":"10.1016\/j.clinthera.2016.09.010_bib183","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1331\/JAPhA.2012.12051","article-title":"Histamine-1 receptor antagonism for treatment of insomnia","author":"Vande Griend","year":"2012","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10.1016\/j.clinthera.2016.09.010_bib184","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.smrv.2014.06.001","article-title":"Doxepin for insomnia: a systematic review of randomized placebo-controlled trials","volume":"19","author":"Yeung","year":"2015","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib185","unstructured":"Silenor (doxepin) [package insert]. Morristown, NJ. Pernix Therapeutics, LLC; 2011."},{"key":"10.1016\/j.clinthera.2016.09.010_bib186","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/1715163514543856","article-title":"Use of ultra-low-dose (\u22646 mg) doxepin for treatment of insomnia in older people","volume":"147","author":"Rojas-Fernandez","year":"2014","journal-title":"Can Pharm J (Ott)"},{"key":"10.1016\/j.clinthera.2016.09.010_bib187","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/sleep\/33.11.1553","article-title":"Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia","volume":"33","author":"Krystal","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib188","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.4088\/JCP.v69n1005","article-title":"Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study","volume":"69","author":"Scharf","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib189","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","article-title":"Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia","volume":"30","author":"Roth","year":"2007","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib190","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.sleep.2010.07.006","article-title":"Efficacy and safety of doxepin 6 mg in a model of transient insomnia","volume":"11","author":"Roth","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib191","first-page":"1433","article-title":"Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia","volume":"34","author":"Krystal","year":"2011","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib192","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3122\/jabfm.17.3.212","article-title":"Treatment of primary insomnia","volume":"17","author":"Ringdahl","year":"2004","journal-title":"J Am Board of Family Practice"},{"key":"10.1016\/j.clinthera.2016.09.010_bib193","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003088-199324020-00004","article-title":"Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications","volume":"24","author":"von Moltke","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.09.010_bib194","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jad.2013.01.021","article-title":"Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder","volume":"149","author":"Locklear","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2016.09.010_bib195","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","article-title":"American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults","volume":"60","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.clinthera.2016.09.010_bib196","first-page":"3","article-title":"Atypical antipsychotics: sleep, sedation, and efficacy","volume":"6","author":"Miller","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib197","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2146\/ajhp130221","article-title":"Quetiapine for insomnia: a review of the literature","volume":"71","author":"Anderson","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2016.09.010_bib198","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.09.010_bib199","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.sleep.2015.11.002","article-title":"Efficacy of gabapentin enacarbil in adult patients with severe primary restless legs syndrome","volume":"19","author":"Lee","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib200","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.5664\/jcsm.4110","article-title":"A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance","volume":"10","author":"Furey","year":"2014","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib201","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/17425255.2013.759209","article-title":"Understanding the pharmacokinetics of anxiolytic drugs","volume":"9","author":"Altamura","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib202","unstructured":"Neurontin (gabapentin) [package insert]. New York, NY. Parke Davis; 2015."},{"key":"10.1016\/j.clinthera.2016.09.010_bib203","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.5664\/jcsm.4108","article-title":"A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance","volume":"10","author":"Rosenberg","year":"2014","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib204","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.sleep.2006.03.018","article-title":"Use of pramipexole in REM sleep behavior disorder: results from a case series","volume":"7","author":"Schmidt","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib205","unstructured":"Mirapex (pramipexole) [package insert]. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc.; 2016."},{"key":"10.1016\/j.clinthera.2016.09.010_bib206","unstructured":"Gabitril (tiagabine) [package insert]. North Wales, PA. Teva Pharmaceuticals USA, Inc.; 2015."},{"key":"10.1016\/j.clinthera.2016.09.010_bib207","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sleep.2005.06.004","article-title":"An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia","volume":"6","author":"Roth","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib208","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1081-1206(10)62855-4","article-title":"H1-receptor antagonists: safety issues","volume":"83","author":"Estelle","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib209","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1389200033489523","article-title":"Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird\u05f3s eye view","volume":"4","author":"Sharma","year":"2003","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.clinthera.2016.09.010_bib210","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/j.1552-4604.1983.tb02730.x","article-title":"Diphenhydramine in insomniac family practice patients: a double-blind study","volume":"23","author":"Rickels","year":"1983","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib211","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/j.1552-4604.1990.tb03592.x","article-title":"Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study","volume":"30","author":"Kudo","year":"1990","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib212","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/sleep\/28.11.1465","article-title":"Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial","volume":"28","author":"Morin","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib213","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/JCP.0b013e31816a9e4f","article-title":"Effects of 2-week treatment with temazepam and diphenhydramine in elderly insomniacs: a randomized, placebo-controlled trial","volume":"28","author":"Glass","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib214","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1001\/archinte.161.17.2091","article-title":"Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients","volume":"161","author":"Agostini","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib215","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/sleep\/29.7.957","article-title":"Characterizing impaired functional alertness from diphenhydramine in the elderly with performance and neurophysiologic measures","volume":"29","author":"McEvoy","year":"2006","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib216","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cger.2007.08.002","article-title":"Complementary and alternative medicine for sleep disturbances in older adults","volume":"24","author":"Gooneratne","year":"2008","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.clinthera.2016.09.010_bib217","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0269881105053309","article-title":"Medicinal plants for insomnia: a review of their pharmacology, efficacy and tolerability","volume":"19","author":"Wheatley","year":"2005","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib218","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/ptr.3151","article-title":"Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women","volume":"24","author":"Anderson","year":"2010","journal-title":"Phytother Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib219","first-page":"220","article-title":"Synaptosomal GABA release as influenced by valerian root extract\u2014involvement of the GABA carrier","volume":"327","author":"Santos","year":"1994","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.clinthera.2016.09.010_bib220","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/S0024-3205(02)01964-1","article-title":"Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors","volume":"71","author":"Muller","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2016.09.010_bib221","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.molbrainres.2005.04.009","article-title":"Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro","volume":"138","author":"Dietz","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib222","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0091-3057(82)90264-7","article-title":"Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man","volume":"17","author":"Leathwood","year":"1982","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.clinthera.2016.09.010_bib223","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/ptr.1574","article-title":"A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults","volume":"18","author":"Diaper","year":"2004","journal-title":"Phytother Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib224","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2000-7972","article-title":"Critical evaluation of the effect of valerian extract on sleep structure and sleep quality","volume":"33","author":"Donath","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib225","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0278-5846(01)00305-0","article-title":"Can valerian improve the sleep of insomniacs after benzodiazepine withdrawal?","volume":"26","author":"Poyares","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib226","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2007-1014295","article-title":"The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study","volume":"27","author":"Schulz","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib227","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-2007-991100","article-title":"The influence of valerian treatment on \"reaction time, alertness and concentration\" in volunteers","volume":"32","author":"Kuhlmann","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2016.09.010_bib228","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00207450802328607","article-title":"Melatonin and melatonergic drugs on sleep: possible mechanisms of action","volume":"119","author":"Srinivasan","year":"2009","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.clinthera.2016.09.010_bib229","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40266-014-0178-0","article-title":"Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature","volume":"31","author":"Vural","year":"2014","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2016.09.010_bib230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bmj.309.6948.167","article-title":"Sleep disorders and melatonin rhythms in elderly people","volume":"309","author":"Haimov","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2016.09.010_bib231","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/0-306-46814-X_51","article-title":"Melatonin as a marker and phase-resetter of circadian rhythms in humans","volume":"460","author":"Lewy","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2016.09.010_bib232","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1210\/jc.2003-030460","article-title":"Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones","volume":"88","author":"Rajaratnam","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2016.09.010_bib233","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(95)91382-3","article-title":"Improvement of sleep quality in elderly people by controlled-release melatonin","volume":"346","author":"Garfinkel","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.09.010_bib234","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-079X.1998.tb00557.x","article-title":"Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment","volume":"25","author":"Jean-Louis","year":"1998","journal-title":"J Pineal Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib235","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/sleep\/26.7.893","article-title":"A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer\u05f3s disease","volume":"26","author":"Singer","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2016.09.010_bib236","first-page":"1","article-title":"Melatonin for treatment of sleep disorders","volume":"108","author":"Buscemi","year":"2004","journal-title":"Evid Rep Technol Assess (Summ)"},{"key":"10.1016\/j.clinthera.2016.09.010_bib237","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1440-1819.1998.tb01063.x","article-title":"Melatonin treatment for circadian rhythm sleep disorders","volume":"52","author":"Okawa","year":"1998","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.clinthera.2016.09.010_bib238","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(05)64715-0","article-title":"Melatonin and fragmented sleep patterns","volume":"348","author":"Middleton","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.09.010_bib239","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-079X.1998.tb00385.x","article-title":"Effect of daytime oral melatonin administration on neurobehavioral performance in humans","volume":"25","author":"Rogers","year":"1998","journal-title":"J Pineal Res"},{"key":"10.1016\/j.clinthera.2016.09.010_bib240","first-page":"249","article-title":"Treatment of insomnia: an alternative approach","volume":"5","author":"Attele","year":"2000","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.clinthera.2016.09.010_bib241","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jch.12041","article-title":"Analysis of recent papers in hypertension: treatment of obstructive sleep apnea with continuous positive airway pressure appears to decrease the incidence of incident hypertension","volume":"15","author":"Bloch","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816307330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816307330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T14:36:15Z","timestamp":1601130975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816307330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":241,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0149291816307330"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.09.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of Safety and Efficacy of Sleep Medicines in Older Adults","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}